tradingkey.logo
tradingkey.logo
Search

Certara Inc

CERT
Add to Watchlist
4.480USD
-0.130-2.82%
Close 05/15, 16:00ETQuotes delayed by 15 min
686.90MMarket Cap
LossP/E TTM
View Detailed Chart
Intraday
1m
30m
1h
D
W
M
D

Today

-2.82%

5 Days

-29.00%

1 Month

-27.27%

6 Months

-46.22%

Year to Date

-49.15%

1 Year

-62.29%

TradingKey Stock Score of Certara Inc

Currency: USD Updated: 2026-05-15

Key Insights

Certara Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 131 out of 468 in the Software & IT Services industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 7.98.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Certara Inc's Score

Industry at a Glance

Industry Ranking
131 / 468
Overall Ranking
203 / 4482
Industry
Software & IT Services

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Positive

Certara Inc Highlights

StrengthsRisks
Certara, Inc. is a provider of biosimulation technology and solutions for using Model-Informed Drug Development (MIDD) in the global biopharmaceutical industry. It accelerates medicine using biosimulation software, technology and services to transform traditional drug discovery and development. It delivers software products and technology-driven services to customers to carry out and realize the full benefits of biosimulation in drug discovery, preclinical and clinical research, regulatory submissions and market access. Its regulatory science and market access software and services, such as regulatory submissions software, natural language processing and Bayesian analytics. It offers both mechanistic and empirical biosimulation solutions providing clients with a comprehensive offering based on their therapy goals, mechanism of action, and available data sources. Its clients include 2,400 biopharmaceutical companies, academic institutions and regulatory agencies across 70 countries.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 18.20% year-on-year.
Fairly Valued
The company’s latest PE is -47.18, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 177.30M shares, decreasing 20.60% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 30.52K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.77.

Analyst Rating

Based on 14 analysts
Buy
Current Rating
7.983
Target Price
+66.67%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Certara Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Certara Inc Info

Certara, Inc. is a provider of biosimulation technology and solutions for using Model-Informed Drug Development (MIDD) in the global biopharmaceutical industry. It accelerates medicine using biosimulation software, technology and services to transform traditional drug discovery and development. It delivers software products and technology-driven services to customers to carry out and realize the full benefits of biosimulation in drug discovery, preclinical and clinical research, regulatory submissions and market access. Its regulatory science and market access software and services, such as regulatory submissions software, natural language processing and Bayesian analytics. It offers both mechanistic and empirical biosimulation solutions providing clients with a comprehensive offering based on their therapy goals, mechanism of action, and available data sources. Its clients include 2,400 biopharmaceutical companies, academic institutions and regulatory agencies across 70 countries.
Ticker SymbolCERT
CompanyCertara Inc
CEOFeehery (William F)
Websitehttps://www.certara.com/
KeyAI